Guzmán Tirado MG

Idioma: Español
Referencias bibliográficas: 120
Paginas: 5-14
Archivo PDF: 52.72 Kb.

RESUMEN

En 1981, Cuba reportó la primera epidemia de dengue hemorrágico en las Américas, en la cual se reportaron más de 344 203 enfermos, con 10 312 casos graves y muy graves, y 158 fallecidos. En estos 30 años con posterioridad a la epidemia, las acciones de vigilancia, control, e investigaciones realizadas han permitido que el país se mantenga libre de dengue, aunque se han reportado epidemias y transmisiones que han sido interrumpidas. En este trabajo se resumen aspectos de interés relacionados con esta epidemia así como con la vigilancia de laboratorio y los resultados de algunas de las investigaciones realizadas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gubler DJ, Kuno J. Dengue and dengue hemorrhagic fever: CAB International198 Madison Avenue: New York, NY 10016-4341 USA; 1997.

2. Guzmán MG, Kourí G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol. 2003 May;27(1):1-13.

3. PAHO. Dengue and Dengue Hemorrhagic Fever in the Americas. Pan American Health Organization Guidelines for Prevention and Control: Scientific Publication; 1994. p. 548.

4. Hoffman WH. La endemicidad pandémica del dengue en los países cálidos. Rev Med Trop Parasit. 1943;9:11-8.

5. Mas P. Dengue fever in Cuba in 1977. PAHO. 1978;375:40-3.

6. Cantelar de Francisco N, Fernández A, Albert Molina L, Pérez Balbis E. Circulación de dengue en Cuba. 1978-1979. Rev Cubana Med Trop. 1981;33(1):72-8.

7. Terry H, Figueredo R, Martínez S, Armando J, Trigo J, Antuna T, et al. Preliminary report on the national extermination campaign of Aedes (S) aegypti in the Republic of Cuba (31 May 1981 to 20 March 1982). Z Gesamte Hyg. 1984;30(12):737-8.

8. Kourí GP, Guzmán MG, Bravo JR, Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ. 1989;67(4):375-80.

9. Martínez-Torres E. Dengue and hemorrhagic dengue: the clinical aspects. Salud Publica Mex. 1995;37(Suppl):S29-44.

10. Guzmán MG, Kourí G, Morier L, Soler M, Fernández A. A study of fatal hemorrhagic dengue cases in Cuba, 1981. Bull Pan Am Health Organ. 1984;18(3):213-20.

11. Guzmán MG, Kourí G, Martínez E, Bravo J, Riverón R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/ /DSS). Bull Pan Am Health Organ. 1987;21(3):270-9.

12. Díaz A, Kourí G, Guzmán MG, Lobaina L, Bravo J, Ruiz A, et al. Description of the clinical picture of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) in adults. Bull Pan Am Health Organ. 1988;22(2):133-44.

13. Guzmán MG, Kourí GP, Bravo J, Soler M, Vázquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg. 1990;42(2):179-84.

14. Armada Gessa JA, Figueredo González R. Application of environmental management principles in the program for eradication of Aedes (Stegomyia) aegypti (Linneus, 1762) in the Republic of Cuba, 1984. Bull Pan Am Health Organ. 1986;20(2):186-93.

15. Kourí Flores G, Guzmán Tirado MG, Bravo González J, Calunga Ríos M. Actividades del laboratorio de arbovirología durante la epidemia de dengue hemorrágico en Cuba, 1981. Rev Cubana Med Trop. 1982;34(2):107-13.

16. Kourí G, Mas P, Guzmán MG, Soler M, Goyenechea A, Morier L. Dengue hemorrhagic fever in Cuba, 1981: rapid diagnosis of the etiologic agent. Bull Pan Am Health Organ. 1983;17(2):126-32.

17. Guzmán Tirado MG, Kourí Flores G, Soler Nodarse M, Morier Díaz L, Vázquez Ramudo S. Aislamiento del virus del dengue 2 en sueros de pacientes utilizando el ratón lactante y cultivo de células LLCMK2. Rev Cubana Med Trop. 1984;36(1):4-10.

18. Guzmán MG, Kourí GP, Bravo J, Calunga M, Soler M, Vázquez S, et al. Dengue haemorrhagic fever in Cuba. I. Serological confirmation of clinical diagnosis. Trans R Soc Trop Med Hyg. 1984;78(2):235-8.

19. Guzmán MG, Kourí GP, Bravo J, Soler M, Vázquez S, Santos M, et al. Dengue haemorrhagic fever in Cuba. II. Clinical investigations. Trans R Soc Trop Med Hyg. 1984;78(2):239-41.

20. Bravo JR, Guzmán MG, Kourí GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg. 1987;81(5):816-20.

21. Martínez E, Guzmán MG, Valdés M, Soler M, Kourí G. Fiebre del dengue y dengue hemorrágico en infantes con infección primaria. Rev Cubana Med Trop. 1993;45(2):97-101.

22. Kourí G, Guzmán MG, Bravo JR. Criterios utilizados durante la epidemia de dengue hemorrágico para definir los casos positivos y las respuestas primarias y secundarias en la prueba de inhibición de la hemaglutinación, Cuba 1981. Rev Cubana Med Trop. 1983;35(1):4-10.

23. Kourí GP, Guzmán MG, Bravo JR. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans R Soc Trop Med Hyg. 1987;81(5):821-3.

24. Guzmán MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, et al. Dengue: a continuing global threat. Nature Rew Microbiol. 2010: S7-S16.

25. WHO. Dengue. Guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009.

26. San Martín JL, Brathwaite O, Zambrano B, Solorzano JO, Bouckenooghe A, Dayan GH, et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010;82(1):128-35.

27. Kourí G, Guzmán MG, Valdés L, Carbonel I, del Rosario D, Vázquez S, et al. Reemergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba. Emerg Infect Dis. 1998;4(1):89-92.

28. Pelaez O, Guzmán MG, Kourí G, Pérez R, Martín JLS, Vázquez S, et al. Dengue 3 epidemic in Havana, 2001. Emerg Infect Dis. 2004;10(4):219-22.

29. Valdés L, Guzmán MG, Kourí G, Delgado J, Carbonell I, Cabrera MV, et al. Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997. Rev Panam Salud Publica. 1999;6(1):16-25.

30. Guzmán MG, Kourí G, Valdés L, Bravo J, Álvarez M, Vázquez S, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol. 2000;152(9):793-9.

31. Guzmán MG, Álvarez A,Vázquez S, Álvarez M, Rosario D, Pelaez O, et al. Epidemiologic studies on dengue 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Inf Dis. 2011.

32. Álvarez M, Rodríguez-Roche R, Bernardo L, Vázquez S, Morier L, González D, et al. Dengue Hemorrhagic Fever Caused by Sequential Dengue 1-3 Virus Infections over a Long Time Interval: Havana Epidemic, 2001-2002. Am J Trop Med Hyg. 2006;75(6):1113-7.

33. Álvarez MPA, Vázquez S, Morier L, Álvarez AM, Guzmán MG. Secuencias de infección viral asociadas a la fiebre del dengue durante la epidemia de dengue 3 de ciudad de La Habana, 2001-2002. Rev Cubana Med Trop. 2008;60(1):26-30.

34. Pérez AB, Sierra B, García G, Aguirre E, Babel N, Álvarez M, et al. Tumor necrosis factor-alpha, transforming growth factor-beta1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol. 2010;71(11):1135-40.

35. Pérez AB, García G, Sierra B, Álvarez M, Vázquez S, Cabrera MV, et al. IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol. 2004;73(2):230-4.

36. Guzmán MG, Kourí G, Valdés L, Bravo J, Vázquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002;11(4):223-7.

37. Guzmán MG, Álvarez M, Rodríguez-Roche R, Bernardo L, Montes T, Vázquez S, et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007; 13(2):282-6.

38. Sierra B, García G, Pérez AB, Morier L, Rodríguez R, Álvarez M, et al. Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis. 2002;6(2):125-8.

39. Sierra BD, García G, Pérez AB, Morier L, Álvarez M, Kourí G, et al. Ethnicity and Difference in Dengue Virus-Specific Memory T Cell Responses in Cuban Individuals. Viral Immunol. 2006;19(4):662-8.

40. de la CSB, Kourí G, Guzmán MG. Race: a risk factor for dengue hemorrhagic fever. Arch Virol. 2007;152(3):533-42.

41. Sierra B, Alegre R, Pérez AB, García G, Sturn-Ramírez K, Obasanjo O, et al. HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: Advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol. 2007;68(6):531-40.

42. Pérez AB, Sierra B, García G, Aguirre E, Babel N, Álvarez M, et al. Tumor necrosis factor-alpha transforming growth factor-1, and interleukin-1- gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Human Immunol. 2010;71:1135-40.

43. García G, Sierra B, Morier L, Guzmán M, Álvarez M, Pérez AP, et al. IL-2 level in past dengue infection. Dengue Bull. 2001;25:65-8.

44. Sierra B, Pérez AB, Vogt K, García G, Schmolke K, Aguirre E, et al. Secondary heterologous dengue infection risk: disequilibrium between immune regulation and inflammation. Cellular Immunol. 2010;262:134-40.

45. García G, Puerto FD, Pérez AB, Sierra B, Aguirre E, Kikuchi M, et al. Association of MICA and MICB alleles with symptomatic dengue infection. Human Immunol. 2011;72:904-7.

46. Guzmán MG, Deubel V, Pelegrino JL, Rosario D, Marrero M, Sariol C, et al. Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg. 1995;52(3):241-6.

47. Álvarez M, Guzmán MG, Rosario D, Vázquez S, Pelegrino JL, Sariol CA, et al. Direct sequencing of an amplified productfrom a serum sample. Rev Cubana Med Trop. 1996;48(1):53-5.

48. Sariol CA, Pelegrino JL, Martínez A, Arteaga E, Kourí G, Guzmán MG. Detection and genetic relationship of dengue virus sequences in seventeen-year-old paraffin-embedded samples from Cuba. Am J Trop Med Hyg. 1999;61(6):994-1000.

49. Rodríguez-Roche R, Álvarez M, Gritsun T, Halstead S, Kourí G, Gould EA, et al. Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology. 2005;334(2):154-9.

50. Rodríguez-Roche R, Álvarez M, Gritsun T, Rosario D, Halstead S, Kourí G, et al. Dengue virus type 2 in Cuba, 1997: conservation of E gene sequence in isolates obtained at different times during the epidemic. Arch Virol. 2005;150(3):415-25.

51. Rodríguez-Roche R, Álvarez M, Holmes EC, Bernardo L, Halstead S, Kourí G, et al. Dengue virus type 3 in Cuba: Evolution from a Small Outbreak in 2000 to a Major Epidemic in 2001. Emerg Infect Dis. 2005;11(5);773-4.

52. Rodríguez-Roche R, Sánchez L, Burgher Y, Rosario D, Álvarez M, Kourí G, et al. Virus role during intraepidemic increase in dengue disease severity. Vector Borne Zoonotic Dis. 2011;11(6):675-81.

53. Guzmán MG, Kourí G, Halstead SB. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? Lancet. 2000;355(9218):1902-3.

54. Guzmán MG, Kourí G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg. 2008;102(6):522-3.

55. Martínez E. Dengue y dengue hemorrágico. Editorial de la Universidad de Quilmes; 1998. p. 1-269.

56. Martínez Torres E. Preventing deaths from dengue: a space and challenge for primary health care. Rev Panam Salud Publica. 2006;20(1):60-74.

57. González D, Castro O, Pérez J, Martínez E, Vázquez S, Rosario D, et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis. 2005;9:280-5.

58. González AL, Martínez RA, Villar LA. Clinical evolution of dengue in hospitalized patients. Biomedica. 2008;28(4):531-43.

59. González D, Limonta D, Bandera JF, Pérez J, Kourí G, Guzmán MG. Dual infection with dengue virus 3 and human immunodeficiency virus 1 in Havana, Cuba. J Infect Dev Ctries. 2009;3(4):318-20.

60. García GSB, Pérez AB, Aguirre E, Rosado I, González N, Izquierdo A, et al. Asymptomatic dengue infection in a Cuban Population confirms the protective role of the RR variant of the PcRIIa polymorphism. American J Tropical Med Hygiene. 2010;82(6):1153-6.

61. García G, González N, Pérez AB, Sierra B, Aguirre E, Rizo D, et al. Long-term persistence of clinical symptoms in dengueinfected persons and its association with immunological disorders. Int J Infect Dis. 2011;15(1):e38-43.

62. Vázquez S, Ruiz D, Barrero R, Ramírez R, Calzada N, Peña BR, et al. Kinetic of dengue virus NS1 protein in dengue 4 confirmed adults patients. Diagn Microbiol Infect Dis. 2010;68:46-9.

63. Vázquez S, Acosta N, Ruiz D, Calzada N, Álvarez AM, Guzmán MG. Immunoglobulin G antibody response in children and adults with acute dengue 3 infection. J Virol Methods. 2009;159(1):6-9.

64. Vázquez S, Valdivia I, Sánchez A, Calzada N, Guzmán MG. Evaluación del sistema diagnóstico UMELISA DENGUE IgM PLUS. Archivos Venezolanos de Medicina Tropical. 2007;5:4-20.

65. Vázquez S, Cabezas S, Pérez AB, Pupo M, Ruiz D, Calzada N, et al. Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int J Infect Dis. 2007;11:256-62.

66. Vázquez S, Pérez AB, Ruiz D, Rodríguez R, Pupo M, Calzada N, et al. Serological markers during Dengue 3 primary and secondary infections. J Clin Virol. 2005;33(2):132-7.

67. Vázquez S, Valdés O, Pupo M, Delgado I, Álvarez M, Pelegrino JL, et al. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods. 2003;110(2):179-84.

68. Vázquez S, Saenz E, Huelva G, González A, Kourí G, Guzmán M. Detección de IgM contra el virus del dengue en sangre entera absorbida en papel de filtro. Rev Panam Salud Publica. 1998;3(3):174-8.

69. Rosario D, Álvarez M, Díaz J, Contreras R, Rodríguez R, Vázquez S, et al. Reacción en cadena de la polimerasa para la detección rápida y determinación del serotipo de virus del dengue en muestras clínicas. Rev Panam Salud Publica. 1998;4(1):1-5.

70. Rosario Domínguez D, Suárez Moran CM, Rodríguez Roche R, Soler Nodarse M, Guzmán Tirado MG. Identificación rápida de los serotipos del virus del dengue mediante la reacción en cadena de la polimerasa. Rev Cubana Med Trop. 1996;48(3):155-60.

71. Pelegrino JL, Arteaga E, Rodríguez AJ, González E, Frontela MD, Guzmán MG. Normalizacióon de técnicas inmunohistoquímicas para la detección de antígenos del virus dengue en tejidos embebidos en parafina. Rev Cubana Med Trop. 1997;49(2):100-7.

72. Pelegrino JL, Vázquez S, Guzmán MG, Valdivia A, Rogés G. Rapid diagnosis of dengue virus using a novel enzymeimmunosorbent assay (ELISA) kit. In: Tenth Annual Clinical Virology Symposium and Annual Meeting Pan American Group for Rapid Diagnosis: USA;1994. p. 74.

73. Rodríguez-Roche R, Álvarez M, Guzmán MG, Morier L, Kourí G. Comparison of rapid centrifugation assay with conventional tissue culture method for isolation of dengue 2 virus in C6/36-HT cells. J Clin Microbiol. 2000;38(9):3508-10.

74. Pupo-Antunez M, Rodríguez R, Álvarez M, Amin N, Rodríguez H, Otero A, et al. Development of a monoclonal antibody specific to a recombinant envelope protein from dengue virus type 4 expressed in Pichia pastoris. Hybridoma. 2001;20(1):35-41.

75. Pupo Antunez M, Álvarez Vera M, Soto Hernandez M, Rodríguez Sanchez H, Rodríguez Diaz R, Morier Diaz L, et al. Anticuerpos monoclonales al virus dengue 4: espectro de reactividad a los 4 serotipos del dengue. Monoclonal antibodies to dengue virus 4: the spectrum of the reactivity to 4 serotypes of dengue. Rev Cubana Med Trop. 2000;52(2):119-25.

76. Pupo-Antunez M, Rodríguez H, Vázquez S, Vilaseca JC, Álvarez M, Otero A, et al. Monoclonal antibodies raised to the dengue-2 virus (Cuban: A15 strain) which recognize viral structural proteins. Hybridoma. 1997;16(4):347-53.

77. Álvarez AM. Sistema integrado de vigilancia para la prevención del dengue. Municipio Cotorro, La Habana, Cuba. Rev Cubana Med Trop. 2007;59(3):193-201.

78. Díaz CTY, De la Cruz AM, Álvarez AM, Piquero ME, Valero A, Fuentes O. Estrategia intersectorial y participativa con enfoque de ecosalud para la prevención de la transmisión de dengue en el nivel local. Cadernos de Saúde Pública Rio de Janeiro. 2009;25(supl.1):59-70. ISSN 0102-311X.

79. Pérez D, Lefevre P, Sánchez L, Van der Stuyft P. Comment on: Whatdo community-based dengue control programmes achieve? Asystematic review of published evaluations. Trans R Soc Trop Med Hyg. 2007;101:630-1.

80. Toledo ME, Vanlerberghe V, Baly A, Ceballos E, Valdés L, Searret M, et al. Towards active community participation in dengue vector control: results from action research in Santiago de Cuba, Cuba. Trans R Soc Trop Med Hyg. 2006;101:56-63.

81. Toledo Romani ME VV, Pérez D. Achieving sustainability of community-based dengue control in Santiago de Cuba. Social Science Med. 2007;64:976-88.

82. Toledo ME, Rodríguez A, Valdés L, Carrion R, Cabrera G, Banderas D, et al. Evidence on impact of community-based environmental management on dengue transmission in Santiago de Cuba. Trop Med Int Health. 2011;16(6):744-7.

83. Bisset Lazcano JA, Marquetti MC, González B, Mendizabal ME, Navarro A. Abundance of larvae of urban mosquitoes during the campaign of the eradication of Aedes aegypti (Linnaeus, 1762) and of dengue in Cuba (1981-82). Rev Cubana Med Trop. 1985;37(2):161-8.

84. Bisset JA, San Martín JL, Romero JE, Montoya R. Evaluación de la resistencia a insecticidas de una cepa de Aedes aegypti de El Salvador. Rev Panam Salud Pública. 2009;26(3):229-34.

85. Marquetti MC, Bisset JA, García A. Recipientes asociados a la infestación por Aedes aegypti en La Lisa, Ciudad de La Habana, Cuba. Rev Cubana Med Trop. 2009;61(3):232-8.

86. Rodríguez MM, Bisset JA, Pérez O, Montada D, Moya M, Ricardo Y, Valdéz V. Estado de la resistencia a insecticidas y sus mecanismos en Aedes aegypti en el municipio Boyeros. Rev Cubana Med Trop. 2009;61(2):170-6.

87. Rodríguez MM, Ricardo Y, Pérez O, Montada D, Figueredo D, Fuentes. Resistencia a insecticidas organofosforados en Aedes aegypti (Diptera: Culicidae) de Santiago de Cuba en el período 1997-2009. Rev Cubana Med Trop. 2010;62(3):217-23.

88. Bisset JA, Rodríguez MM, Ricardo Y, Ranson H, Pérez O, Moya M, et al. Temephos resistance and esterase activity in the mosquito Aedes aegypti in Havana, Cuba increased dramatically between 2006 and 2008. Medical and Veterinary Entomology. 2011;25(3):233-9.

89. Fuentes O, López R, Marquetti MC, Lugo J. Presence of Aedes (Gymnometopa) mediovittatus in Cuba: a new factor to be considered in the national campaign to eradicate dengue. Bull Pan Am Health Organ. 1992;26(1):14-7.

90. Guzmán MG, Triana C, Bravo J, Kourí G. The estimation of the economic damages caused as a consequence of the epidemic of hemorrhagic dengue in Cuba in 1981. Rev Cubana Med Trop. 1992;44(1):13-7.

91. Valdés L, Vila J, Guzmán MG. Impacto económico de la epidemia de dengue 2 de Santiago de Cuba, 1997. Rev Cubana Med Trop. 2002;54(3):220-7.

92. Baly O, Vanlerberghe V, Ceballos E, Reyes A, Sánchez I, Carvajal M, et al. Effectiveness of a Community-Based Approach Intertwined with a Vertical Aedes Control Program. Am J Trop Med Hyg. 2009;81(1):88-93.

93. Baly A, Flessa S, Cote M, Thiramanus T, Vanlerberghe V, Villegas E, et al. The cost of routine Aedes aegypti control and of insecticide-treated curtain implementation. Am J Trop Med Hyg. 2011;84(5):747-52.

94. Álvarez M, Guzmán MG, Pupo M, Morier L, Bravo J, Rodríguez R. Study of biologic attributes of Cuban dengue 2 virus after serial passage in primary dog kidney cells. Int J Infect Dis. 2001;5(1):35-9.

95. Mune M, Rodríguez R, Ramírez R, Soto Y, Sierra B, Rodríguez Roche R, et al. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch Virol. 2003;148(11):2267-73.

96. Sierra Vázquez B, Pérez Díaz AB, Vázquez Villasuso V, Rodríguez Díaz R, García Menéndez G, Guzmán Tirado MG. Assessment of the cellular immune response induced in Balb/ C mice with dengue virus 2 envelope protein. Rev Cubana Med Trop. 1999;51(2):95-8.

97. Guzmán MG, Rodríguez R, Hermida L, Álvarez M, Lazo L, Mune M, et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg. 2003;69(2):129-34.

98. Guillen G, Aguilar JC, Duenas S, Hermida L, Guzmán MG, Penton E, et al. Virus-like particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. Procedia Vaccinology. 2010;2:128-33.

99. Guzmán MG, Hermida L, Bernardo L, Ramírez R, Guillen G. Domain III of the envelope protein as a dengue vacine target. Expert Rev Vaccines. 2010;9(9):87-97.

100. Guzmán MG. Dengue vaccines: new developments. Drugs Future. 2011;36(1):45-62.

101. Hermida L, Rodríguez R, Lazo L, López C, Márquez G, Paez R, et al. A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immuneaffinity chromatography purified counterpart. J Biotechnol. 2002;94(2):213-6.

102. Hermida L, Rodríguez R, Lazo L, Bernardo L, Silva R, Zulueta A, et al. A fragment of the Envelope protein from Dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem. 2003;39:107-14.

103. Hermida L, Rodríguez R, Lazo L, Silva R, Zulueta A, Chinea G, et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods. 2004;115(1):41-9.

104. Hermida L, Bernardo L, Martín J, Álvarez M, Prado I, López C, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. 2006;24(16):3165-71.

105. Izquierdo A, Bernardo L, Martín J, Santana E, Hermida L, Guillen G, et al. Serotype-specificity of recombinant fusion proteins containing Domain III of dengue virus. Virus Res. 2008;138(1-2):135-8.

106. Valdés I, Hermida L, Zulueta A, Martín J, Silva R, Álvarez M, et al. Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol Biotechnol. 2007;35(1):23-30.

107. Valdés I, Hermida L, Martín J, Menéndez T, Gil L, Lazo L, et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of Dengue 2 and two components of Neisseria meningitidis. Vaccine. 2009;27:995-1001.

108. Valdés I, Bernardo L, Gil L, Pavón A, Lazo L, López C, et al. A novel fusion protein domain III-capsid from dengue- 2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology. 2009; 394(2):249-58. 109. Valdés I, Hermida L, Gil L, Lazo L, Castro J, Martín J, et al. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis. 2009;14(5):e377-83.

109. Valdés I, Gil L, Romero Y, Castro J, Puente P, Lazo L, et al. The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN- 2. Clin Vaccine Immunol. 2011;18(3):455-9.

110. Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007;25(6):1064-70.

111. Lazo L, Zulueta A, Hermida L, Blanco A, Sánchez J, Valdés I, et al. The Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnology Applied Biochemistry. 2008.52:265-267.

112. Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdés I, et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem. 2009;52(Pt 4):265-71.

113. Lazo L, Gil L, López C, Valdés I, Marcos E, Álvarez M, et al. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol. 2010;155(10):1587-95.

114. Bernardo L, Yndart A, Vázquez S, Morier L, Guzmán MG. Antibody responses to asian and american genotypes of dengue 2 virus in immunized mice. Clin Diagn Lab Immunol. 2005;12(2):361-2.

115. Bernardo L, Izquierdo A, Prado I, Rosario D, Álvarez M, Santana E, et al. Primary and Secondary Infections by Asian and American Genotypes of Dengue 2 Virus in Macaca Fascicularis Monkeys. Clin Vaccine Immunol. 2007; 15(3):439-46.

116. Bernardo L, Hermida L, Martín J, Álvarez M, Prado I, Lopez C, et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol. 2008;153(5): 849-54.

117. Bernardo L, Izquierdo A, Álvarez M, Rosario D, Prado I, López C, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in nonhuman primates. Antiviral Research. 2008;80:194-9.

118. Bernardo L, Izquierdo A, Prado I, Rosario D, Álvarez M, Santana E, et al. Primary and Secondary Infections by Asian and American Genotypes of Dengue 2 Virus in Macaca Fascicularis Monkeys. Clin Vaccine Immunol. 2008;15(3):439-46.

119. Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzmán MG. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol. 2009;16(12):1829-31.

120. Bernardo L, Pavon A, Hermida L, Gil L, Valdés I, Cabezas S, et al. The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine. 2011; 29(25):4256-63.